CD300C activators represent a niche category of chemical modulators that specifically target the CD300C molecule, a member of the CD300 family of receptors which are type I transmembrane proteins. The CD300C receptor is known to be involved in the regulation of a variety of cellular signaling pathways, often associated with immune cell function. The activators in this chemical class are structured to bind with CD300C and modulate its activity, which can result in the alteration of downstream signaling cascades. This modulation is typically achieved through the engagement of the extracellular domain of CD300C, which might then trigger either a direct activation of the receptor or facilitate its interaction with other signaling molecules, thus influencing the receptor's function. The design of CD300C activators is complex, as it requires a precise understanding of the receptor's structure and the conformational changes that can lead to activation.
The process of discovering and developing CD300C activators involves an interdisciplinary approach, leveraging insights from cellular biology, immunology, and chemical synthesis. The initial phase often involves detailed studies of the CD300C receptor's extracellular domain to identify potential binding sites that are conducive to the attachment of small molecules or biologics that can act as activators. These findings inform the synthesis of initial chemical compounds, which are then iteratively tested and refined to improve their specificity and efficacy in engaging with CD300C. Techniques such as computational modeling, affinity chromatography, and surface plasmon resonance may be employed to gauge the interaction between potential activators and the CD300C receptor. These activators must demonstrate a high degree of selectivity to avoid unintended interactions with other members of the CD300 family or unrelated receptors, which requires a keen understanding of the subtle differences in receptor structures. Through meticulous research and development, compounds that can effectively target CD300C are synthesized and optimized, contributing to the body of knowledge surrounding the modulation of receptor-mediated signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $48.00 $300.00 $572.00 $1040.00 $2601.00 $4682.00 | 1 | |
Adenosine interacts with adenosine receptors, which can modulate immune cell activity. This interaction has the potential to enhance the immunoregulatory functions of CD300C by promoting an anti-inflammatory environment in which CD300C is more active. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin is known to modulate NF-κB pathway, which is implicated in immune response regulation. By inhibiting NF-κB, curcumin may enhance the immunomodulatory activity of CD300C on myeloid cells by fostering a context that favors its activation. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol, a SIRT1 activator, might influence the immune response by affecting NF-κB signaling. By activating SIRT1, resveratrol could potentiate the anti-inflammatory response, indirectly enhancing the activity of CD300C. | ||||||
Piceatannol | 10083-24-6 | sc-200610 sc-200610A sc-200610B | 1 mg 5 mg 25 mg | $51.00 $71.00 $199.00 | 11 | |
Piceatannol inhibits Syk kinase, which is involved in the signaling pathways of various immune receptors. By inhibiting Syk kinase, piceatannol could enhance CD300C-mediated signaling by reducing the competitive inhibition within the immune signaling network. | ||||||
Cholecalciferol | 67-97-0 | sc-205630 sc-205630A sc-205630B | 1 g 5 g 10 g | $71.00 $163.00 $296.00 | 2 | |
Vitamin D3 modulates immune function through the Vitamin D receptor. By promoting an anti-inflammatory state, Vitamin D3 can enhance the regulatory roles of CD300C on immune cells. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Zinc is an essential mineral that plays a significant role in immune system function. Zinc gluconate, by supporting immune cell function, could enhance the activity of CD300C through improved cellular responses. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin affects PI3K/Akt signaling and has been shown to have immunomodulatory properties. By influencing this pathway, quercetin may enhance CD300C's activity indirectly by modulating immune cell function. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $153.00 $292.00 $489.00 $1325.00 $8465.00 $933.00 | 22 | |
Sulforaphane impacts the Nrf2 pathway, which regulates the expression of antioxidant proteins that protect against oxidative damage during immune responses. This can, in turn, enhance CD300C activity by promoting immune cell resilience. | ||||||
Glycine | 56-40-6 | sc-29096A sc-29096 sc-29096B sc-29096C | 500 g 1 kg 3 kg 10 kg | $41.00 $71.00 $112.00 $357.00 | 15 | |
Glycine is an inhibitory neurotransmitter but also modulates immune responses. By affecting immune cell activity, glycine could enhance the activity of CD300C through its immunomodulatory effects. | ||||||
Docosa-4Z,7Z,10Z,13Z,16Z,19Z-hexaenoic Acid (22:6, n-3) | 6217-54-5 | sc-200768 sc-200768A sc-200768B sc-200768C sc-200768D | 100 mg 1 g 10 g 50 g 100 g | $94.00 $210.00 $1779.00 $8021.00 $16657.00 | 11 | |
Omega-3 fatty acids modulate inflammation and immune responses. By altering cell membrane composition and signaling pathways, they can enhance the activity of CD300C by fostering an environment conducive to its activation. | ||||||